The study by Leger et al. on paediatric patients with AML treated with CPX-351 showed baseline hs-cTnT and NT-proBNP values frequently already altered in a heavily pretreated population, a significant increase in hs-cTnT after the CPX-351 cycle, compared with a stably elevated but not further increased NT-proBNP, no clear correlation between biomarker levels and LVEF at the end of treatment [29]. The gene discussed is NPPB; the disease is acute myeloid leukemia.